THE EFFECTS OF EPROSARTAN, AN ANGIOTENSIN-II AT(1) RECEPTOR ANTAGONIST, ON URIC-ACID EXCRETION IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION

The effects of antihypertensive agents, including angiotensin II recep tor antagonists, on urine uric acid excretion may have important clini cal consequences. Therefore, the effects of single and repeated doses of eprosartan on uric acid excretion were evaluated in 57 mole patient s with mild-to-moderate essential hypertension in a double-blind, rand omized, placebo-controlled, repeated dose, dose-rising two-period, per iod-balanced, crossover study conducted in two parts. In part 1 (n = 3 3), the effects of eprosartan dose regimens of of 50 mg, 100 mg, and 3 50 mg once daily and 150 mg every 12 hours on uric acid excretion were assessed. In part 2 (n = 24), the effects of eprosartan dose regimens of 600 mg, 800 mg, and 1,200 mg once daily on uric acid excretion wer e assessed. Eprosartan was well tolerated. There were no appreciable c hanges from predose values in fractional excretion of uric acid (FEua, ,), urine uric acid excretion, urine uric acid to creatinine (U-ua/U-c r) ratios, or serum uric acid concentrations after single or repeated doses of eprosartan. Mean U-ua/U-cr ratios for eprosartan doses of 50 mg, 100 mg, or 350 mg daily or 150 mg every 12 hours were comparable t o those for placebo. Mean FEua values and U-ua/U-cr ratios for eprosar tan doses of 600 mg, 800 mg, br 1,200 mg daily also were comparable to those for placebo. Single and repeated oral doses of eprosartan rangi ng from 50 mg, to 1,200 mg daily had no effect on serum uric acid conc entrations or urine uric acid excretion in patients with mild-to-moder ate essential hypertension. (C) 1998 The American College of Clinical Pharmacology.